Report overview
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Drugs. This report contains market size and forecasts of Kidney Cancer Drugs in global, including the following market information:
Global Kidney Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Kidney Cancer Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Kidney Cancer Drugs companies in 2022 (%)
The global Kidney Cancer Drugs market was valued at US$ 4085 million in 2022 and is projected to reach US$ 5417.4 million by 2029, at a CAGR of 4.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
We surveyed the Kidney Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Global Kidney Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
Global Kidney Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Kidney Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Kidney Cancer Drugs revenues share in global market, 2022 (%)
Key companies Kidney Cancer Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Kidney Cancer Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kidney Cancer Drugs, market overview.
Chapter 2: Global Kidney Cancer Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Kidney Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kidney Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Kidney Cancer Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
